Transdermal Scopolamine Market – Global Industry Analysis, Market Size Estimation and Growth Forecast by Regions (North America, Asia Pacific, Europe, Middle East & Africa and Latin America), 2017 – 2025

The global transdermal scopolamine market was worth US $370 million in 2017, and it is expected to grow at a CAGR of 4.5% between 2017 and 2025.

Transdermal Scopolamine Market – Introduction

The global transdermal scopolamine market is expected to grow fast during the forecast period of 2017 to 2025. In the transdermal scopolamine market report, the market is segmented based on region. Scopolamine is primarily used to treat motion sickness and postoperative nausea and vomiting, apart from treating seasickness, irritable bowel syndrome, and eye inflammation, among others.

Scopolamine was first used in 1947 and is obtained from Scopolia, a type of nightshade plant variant. Scopolamine can be administered by various routes, such as transdermal, rectal, buccal, subcutaneous, sublingual, intramuscular, and intravenous. The transdermal route of scopolamine administration is one of the most popular and is considered to be a very convenient mode of self-administration by patients. The transdermal scopolamine market size and volume are primarily being driven by the increasing applications for reducing postoperative nausea and vomiting.

Report Overview

Segmentation Overview

Market Dynamics

The number of surgical procedures occurring per year globally is estimated to have grown by approximately 38% in the last 8 years, as per the studies conducted by the World Health Organization (WHO) and the Organization for Economic Cooperation and Development (OECD). Such widespread growth in the number of surgical procedures has been the primary driver for the transdermal scopolamine market. Prescription of transdermal scopolamine is primarily done to tackle anesthesia-induced vomiting and nausea in postoperative patients.

Additionally, the transdermal scopolamine patch has been seeing increasing application in emerging economies. The rate of growth in the number of surgical procedures is much higher in such countries, and owing to the growing awareness regarding the benefits of these transdermal scopolamine patches, the demand has also been increasing at a fast pace. The high level of awareness regarding the advantages of transdermal scopolamine in developed nations has also resulted in higher over-the-counter (OTC) sales of these patches. These factors have all contributed to the growth of the transdermal scopolamine market.

Adverse effects, such as drowsiness and retarded motion, among others, and adverse withdrawal symptoms are some of the factors which have been restraining the growth of the transdermal scopolamine market globally. However, the increasing usage of scopolamine patches by various tourists has been instrumental in positively impacting the transdermal scopolamine market growth trends. The increasing rates of awareness and growing rates of surgery in emerging economies are some of the other factors that are expected to offer good growth opportunities for the transdermal scopolamine market.

Market Segmentation Overview

By geography, the market has been segmented into Asia Pacific, North America, the Middle East & Africa (MEA), Europe, and Latin America. In terms of revenue, North America accounted for the largest market share of the transdermal scopolamine market, followed by Europe. The growth in the total number of surgical procedures, coupled with high awareness of the benefits offered by transdermal scopolamine patches, are the primary growth drivers for the North American market for transdermal scopolamine. Asia-Pacific is expected to become the second-largest market for transdermal scopolamine by 2025, owing to the fast growth in prescriptions for transdermal scopolamine patches.

Competitive Landscape

Transdermal scopolamine market competition is primarily between a few manufacturers, owing to the consolidated nature of the market. Major companies operating in the transdermal scopolamine market are GlaxoSmithKline Plc (England), Baxter International, Inc. (the U.S.), Perrigo Company Plc (the U.S.), Novartis International AG (Switzerland), and Myungmoon Pharma Co., Ltd. (South Korea), among others.

Major Players